Ulcerative Colitis
Conditions
Brief summary
This is a pilot study of combination therapy using FMT and vedolizumab for induction of UC. The investigators hypothesize that a combination therapy approach which addresses immune trafficking and microbial manipulation simultaneously will lead to superior outcomes than those seen with single agent therapy.
Detailed description
This is a prospective pilot trial involving a single centre (McMaster University Medical Centre) recruiting patients from Hamilton, Ontario Canada and the surrounding regions, to evaluate efficacy and safety outcomes when using fecal microbiota transplantation once weekly for six weeks in UC patients who are initiated on vedolizumab. A lead in study will be conducted with the first five patients to ensure engraftment of FMT within the colon. Interim analysis will be conducted after these five patients to ensure engraftment within the colon. Data Safety and Monitoring Board will also be informed of the results after the first five patients, including any adverse events. Decision will be made based on these results whether to proceed with the prospective study using FMT weekly for six weeks, or whether to modify the dose/frequency of FMT treatment. As patients with previous biologic failure tend to have sub-optimal response to vedolizumab monotherapy, this pilot study will focus on recruitment of previous biologic failure patients.
Interventions
BIOLOGICALFecal microbiota transplantation
Use of fecal microbiota transplantation enemas once weekly in patients who are initiating vedolizumab treatment
Sponsors
McMaster University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients aged 18 or over 2. Active UC defined as total Mayo score of 6 or more points, with endoscopic subscore at \> 2 3. Clinician initiating vedolizumab for patients as per standard of care for UC 4. Patient previously has been exposed to one or more biologic or advanced therapies (anti-TNF, JAK inhibitor, anti-interleukin) and never previously exposed to vedolizumab or other anti-integrin therapy. 5. Females of child bearing potential must be willing and able to use acceptable contraception as per Appendix III. II. b. Toxicity section of the Health Canada Guidance
Exclusion criteria
1. Participating in another clinical trial 2. Unable to give informed consent 3. Severe comorbid medical illness 4. Concomitant Clostridium difficile infection 5. Increase in medical therapy for UC in the last 4 weeks. Continued treatment with 5-ASA, azathioprine, or 6-mercaptopurine will be permitted if taken at stable dose for ≥4 weeks prior to study entry. Stable dose (same dose for at least 2 weeks) or a tapering dose of steroids will also be permitted provided the dose of steroid is not increased again. Stable intake of probiotic therapy also permitted. 6. New antibiotic therapy in the last 28 days. 7. Dose of infliximab or golimumab in prior four weeks, adalimumab in prior two weeks, or tofacitinib in prior one week. 8. Pregnant women. 9. Clinically significant lactose intolerance 10. Any condition, in the opinion of the investigator, that the treatment may pose a health risk to the subject, based on lab study results
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical remission | Week 6 | The primary outcome of this pilot trial is rate of remission of UC, defined as a total Mayo score of 2 or less, with no subscore greater than 1, and endoscopic healing with a endoscopic subscore of 0 or 1. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical response | Week 6 | Evaluation of fecal microbiota transplant and vedolizumab for rate of clinical response (defined as reduction of Mayo score of 2 or more points) at the end of the trial. |
| Endoscopic improvement | Week 6 | Evaluation of fecal microbiota transplant and vedolizumab at rate of endoscopic improvement (defined as reduction of endoscopic Mayo score of 1 or more) at the end of the trial. |
| Compliance | Week 6 | Evaluate the number of patients who complete all their FMT and vedolizumab induction visits |
| Mucosal microbiome | Week 6 | Compare the mucosal microbiome in UC patients in remission versus still active at the end of the trial. |
| Adverse events | Week 6 | Qualitative evaluation of adverse events in patients receiving fecal microbiota transplant and vedolizumab |
| Fecal microbiome | Week 6 | Compare the fecal microbiome in UC patients in remission versus still active at the end of the trial. |
Countries
Canada
Outcome results
None listed